SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

25 Jul 2018 07:00

RNS Number : 6057V
James Halstead PLC
25 July 2018
 

25 July 2018

 

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2018.

 

We are pleased to report that sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales. The Chairman, in that statement, noted that a German competitor had entered administration and at that time we decided to undertake our largest ever re-vamp of our homogenous flooring ranges with the launch of "Palettone."

 

Palettone is a premium homogenous sheet vinyl collection, launched in May 2018. It is the largest new product development by any manufacturer in this core product area in many years. It offers a collection of 50 colours optimised for our global market and is presented in a unique, innovative sample package with full customer support from specification to installation. The feedback we have received on the collection since launch has been exceptional.

 

The costs of development trials, sampling, marketing material and related costs have been around £2 million and the product has just been launched into the global market place. The timescale that our production and marketing staff worked to was ambitious and we are delighted with the successful launch.

 

In line with best practice, we shall expense these costs rather than amortise or construct an adjustment to "underlying" earnings.

 

Consequently we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

Telephone: 0161 767 2500

 

 

Nick Lyon - Hudson Sandler

Telephone: 020 7796 4133

 

 

Ben Thorne

Dominic Morley - Panmure Gordon

(Nominated advisor and broker)

 

Telephone: 020 7886 2500

 

Chris Hardie - Arden Partners

Telephone: 020 7614 5900

(Broker)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBZLFLVDFEBBX
Date   Source Headline
16th Mar 20153:46 pmRNSNotice of Interim Results
3rd Mar 20153:00 pmRNSTotal Voting Rights
30th Jan 20157:00 amRNSPre Close Trading Statement
6th Jan 20154:11 pmRNSBlocklisting Interim Review
6th Jan 201511:21 amRNSTotal Voting Rights
5th Dec 20147:00 amRNSAGM Statement
3rd Nov 20147:00 amRNSTotal Voting Rights
24th Oct 20143:24 pmRNSAnnual Financial Report
1st Oct 20149:25 amRNSTotal Voting Rights
1st Oct 20147:00 amRNSPreliminary Results
27th Aug 20147:00 amRNSNotice of Preliminary Results
31st Jul 20147:00 amRNSPre-Close Trading Statement
21st Jul 20143:50 pmRNSDirectors' Shareholdings
17th Jul 20144:51 pmRNSDirectors exercise of share options
1st Jul 20147:00 amRNSBlocklisting Interim Review
1st Jul 20147:00 amRNSTotal Voting Rights
3rd Jun 20147:00 amRNSTotal Voting Rights
1st May 201411:10 amRNSTotal Voting Rights
31st Mar 20147:00 amRNSInterim Results
3rd Feb 20147:00 amRNSPre Close Trading Statement
20th Jan 20149:40 amRNSPurchase of own shares and directors' dealings
6th Jan 20144:30 pmRNSBlocklisting Interim Review
6th Dec 20137:00 amRNSAGM Statement
4th Nov 201311:00 amRNSTotal Voting Rights
28th Oct 20135:25 pmRNSAnnual Financial Report
28th Oct 20134:18 pmRNSDirectors exercise of share options
4th Oct 201312:40 pmRNSTotal Voting Rights
1st Oct 20137:00 amRNSPreliminary Announcement of Audited Results
23rd Sep 201312:55 pmRNSNotice of Preliminary Results
31st Jul 20137:00 amRNSPre-close Trading Statement
16th Jul 201312:00 pmRNSBlocklisting Interim Review
21st Jun 20134:35 pmRNSPrice Monitoring Extension
2nd May 201311:10 amRNSTotal Voting Rights
28th Mar 20137:00 amRNSInterim Results
1st Feb 201311:15 amRNSNotice of Interim Results Date Change
31st Jan 20134:00 pmRNSTotal Voting Rights
31st Jan 20137:00 amRNSPre-close Trading Statement
10th Jan 201311:00 amRNSIssue of Equity and Total Voting Rights
7th Jan 20139:00 amRNSBlocklisting Interim Review
11th Dec 20127:00 amRNSBonus Issue
7th Dec 20124:40 pmRNSSecond Price Monitoring Extn
7th Dec 20124:35 pmRNSPrice Monitoring Extension
7th Dec 20127:00 amRNSAGM Statement
3rd Dec 20127:00 amRNSTotal Voting Rights
1st Nov 20127:00 amRNSTotal Voting Rights
23rd Oct 20127:00 amRNSAnnual Financial Report
1st Oct 20127:00 amRNSPreliminary Audited Results
3rd Sep 20127:00 amRNSTotal Voting Rights
30th Jul 20127:00 amRNSPre-close Trading Statement
2nd Jul 20129:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.